South Florida pharmaceutical firm doubles down on niche drug market


As the market for drugs aimed at treating rare diseases continues to grow, South Florida’s biotechnology companies and pharmaceutical firms are getting in on the action.

Jupiter Orphan Therapeutics is the latest in the region to receive “orphan” drug designation from the U.S. Food and Drug Administration for a product, a major milestone in the path to bringing new medicines to market. (Phillip Frost’s Opko Health is another major player in the niche industry segment.)